Preclinical data have showed that the inhibition of prostaglandin E2 synthesis, a product of the cyclooxygenase-2 (COX-2) pathway, suppresses tumour-promoting inflammation and may enhance immunotherapy response23. The gene discussed is PTGS2; the disease is neoplasm.